echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Liver Cancer: The relationship between baseline liver function and prognosis in patients with unresectable hepatocellular carcinoma: results from the analysis of REFLECT patients from a phase 3 clinical study

    Liver Cancer: The relationship between baseline liver function and prognosis in patients with unresectable hepatocellular carcinoma: results from the analysis of REFLECT patients from a phase 3 clinical study

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The REFLECT study is a global, randomized, open-label, phase III clinical study that evaluates the efficacy of lenvatinib (Lenvatinib) versus sorafenib (sorafenib) in the first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC)
    .


    Studies have shown that lenvatinib is not inferior to sorafenib


    The REFLECT study is a global, randomized, open-label, phase III clinical study that evaluates the efficacy of lenvatinib (Lenvatinib) versus sorafenib (sorafenib) in the first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC)


    The study only included patients with ALBI grade 1 or 2 and CPS grade 5 or 6 who received lenvatinib or sorafenib
    .


    The CPS score was calculated using five indicators: serum bilirubin, serum albumin, ascites, encephalopathy, and INR


    The study only included patients with ALBI grade 1 or 2 and CPS grade 5 or 6 who received lenvatinib or sorafenib


    The median OS of ALBI level 1 patients receiving lenvatinib and sorafenib was 17.


    OS

    OS

    Among patients who received follow-up anti-tumor therapy after lenvatinib treatment, the median OS of ALBI level 1 (n = 158) patients was 20.
    9 months (95% CI: 17.
    6–25.
    9), and ALBI level 2 (n = 46) The patient’s median OS was 15.
    1 months (95% CI: 12.
    2–20.
    8; HR 0.
    643, 95% CI: 0.
    440–0.
    938)
    .

    Among patients who received follow-up anti-tumor therapy after lenvatinib treatment, the median OS of ALBI level 1 (n = 158) patients was 20.
    9 months (95% CI: 17.
    6–25.
    9), and ALBI level 2 (n = 46) The patient’s median OS was 15.
    1 months (95% CI: 12.
    2–20.
    8; HR 0.
    643, 95% CI: 0.
    440–0.
    938)
    .


    The median PFS of ALBI level 1 patients receiving lenvatinib and sorafenib were 7.
    4 months (95% CI: 7.
    2–9.
    1) and 3.
    6 months (95% CI: 3.
    6–4.
    1), respectively; ALBI level 2 The median PFS of patients receiving lenvatinib and sorafenib was 5.
    5 months (95% CI: 3.
    6–7.
    4) and 3.
    5 months (95% CI: 1.
    9–3.
    7), respectively
    .


    In patients with CPS 5 points, the median PFS of receiving lenvatinib and sorafenib were 7.


    The median PFS of ALBI level 1 patients receiving lenvatinib and sorafenib were 7.


                        PFS

    PFS

    In lenvatinib-treated patients, the ORRs of ALBI grade 1 and 2 patients were 45.
    0% and 32.
    3%, respectively; the ORRs of CPS 5 points and 6 points were 42.
    9% and 33.
    6%, respectively
    .


    In patients treated with sorafenib, the ORRs of ALBI grade 1 and 2 patients were 13.


    In lenvatinib-treated patients, the ORRs of ALBI grade 1 and 2 patients were 45.


                  Efficacy evaluation

                 Efficacy evaluation Efficacy evaluation

    In patients treated with lenvatinib, the proportions of ALBI grade 1 and grade 2 patients with ≥ grade 3 treatment-related adverse events (TEAE) were 69.
    5% and 86.
    1%, respectively; while those with CPS scores 5 and 6 were 71.
    6% and 86.
    1%, respectively.
    86.
    0%
    .


    Among patients treated with sorafenib, the proportions of ALBI grade 1 and grade 2 patients with ≥ grade 3 treatment-related adverse events (TEAE) were 62.


    In patients treated with lenvatinib, the proportions of ALBI grade 1 and grade 2 patients with ≥ grade 3 treatment-related adverse events (TEAE) were 69.
    5% and 86.
    1%, respectively; while those with CPS scores 5 and 6 were 71.
    6% and 86.
    1%, respectively.
    86.
    0%
    .
    Among patients treated with sorafenib, the proportions of ALBI grade 1 and grade 2 patients with ≥ grade 3 treatment-related adverse events (TEAE) were 62.
    1% and 77.
    6%, respectively; while those with CPS scores 5 and 6 were 63.
    2% and 63.
    2%, respectively.
    76.
    3%
    .

                  Treatment adverse events

    Treatment adverse events

    In summary, when patients with unresectable hepatocellular carcinoma are treated with lenvatinib or sorafenib, a better baseline liver function (such as ALBI grade or CPS score) may be a prognostic indicator of better survival
    .

    In summary, when patients with unresectable hepatocellular carcinoma are treated with lenvatinib or sorafenib, a better baseline liver function (such as ALBI grade or CPS score) may be a prognostic indicator of better survival
    .
    When patients with unresectable hepatocellular carcinoma are treated with lenvatinib or sorafenib, a good baseline liver function (such as ALBI grade or CPS score) may be a prognostic indicator of better survival
    .
    When patients with unresectable hepatocellular carcinoma are treated with lenvatinib or sorafenib, a good baseline liver function (such as ALBI grade or CPS score) may be a prognostic indicator of better survival
    .

    Original source:

    Original source:

    Arndt Vogel, Catherine Frenette, Max Sung, et al.
    Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.
    Liver Cancer.
    DOI: 10.
    1159/000516490.
    Published online: July 15, 2021

    .
    Arndt Vogel, Catherine Frenette, Max Sung, et al Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma Liver Cancer DOI:.
    .
    10.
    1159 / 000516490 Published online:.
    July 15, 2021 in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.